As of September 30, 2026, Medistim ASA carries a market capitalization of 420.51M, placing it among publicly traded companies globally. Its enterprise value stands at 406.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 420.51M |
| Enterprise Value | 406.79M |
Medistim ASA's next confirmed earnings release is scheduled for February 26, 2027.
| Earnings Date | 2/26/2027 |
As of September 30, 2026, Medistim ASA has 18.28M shares outstanding.
| Shares Outstanding | 18.28M |
As of September 30, 2026, Medistim ASA trades at a trailing price-to-earnings ratio of 25.67. The price-to-sales ratio is 5.75, and the price-to-book ratio stands at 10.07.
| PE Ratio | 25.67 |
| PS Ratio | 5.75 |
| PB Ratio | 10.07 |
| P/TBV Ratio | 13.67 |
| P/FCF Ratio | 21.55 |
| P/OCF Ratio | 21.55 |
As of September 30, 2026, Medistim ASA trades at an EV/EBITDA multiple of 18.48 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.44 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Medistim ASA trades at an EV/FCF ratio of 20.81, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 406.79M versus a market cap of 420.51M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 5.56 |
| EV / EBITDA | 18.48 |
| EV / EBIT | 19.44 |
| EV / FCF | 20.81 |
As of September 30, 2026, Medistim ASA maintains a current ratio of 3.16, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.77, indicating elevated leverage, while an interest coverage ratio of 602.18 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.16 |
| Quick Ratio | 1.25 |
| Debt / Equity | 5.77 |
| Debt / EBITDA | 0.11 |
| Interest Coverage | 602.18 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately 459,745.15 in revenue per employee across its workforce of 159.00, a quick read on workforce productivity versus industry peers.
| Revenue Per Employee | 459,745.15 |
| Employee Count | 159.00 |
Over the twelve months ended September 30, 2026, Medistim ASA recorded 4.75M in income tax expense. That works out to an effective tax rate of 22.47, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 21.13M, leaving 16.38M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 4.75M |
| Effective Tax Rate | 22.47 |
As of the close on October 27, 2026, Medistim ASA's stock has gained approximately 27.27% over the past 52 weeks. The 50-day moving average sits at 24.07, while the 200-day moving average is 21.00.
| 52-Week Price Change | 27.27% |
| 50-Day Moving Average | 24.07 |
| 200-Day Moving Average | 21.00 |
Over the twelve months ended September 30, 2026, Medistim ASA generated 73.10M in revenue and converted that into 16.38M in net income, yielding earnings per share of 0.90. EBITDA reached 22.01M, while operating income came in at 20.92M.
| Revenue | 73.10M |
| Gross Profit | 59.71M |
| Operating Income | 20.92M |
| Pretax Income | 21.13M |
| Net Income | 16.38M |
| EBITDA | 22.01M |
| EBIT | 20.92M |
| Earnings Per Share (EPS) | 0.90 |
As of September 30, 2026, Medistim ASA holds 16.13M in cash and equivalents against 2.41M in total debt, resulting in a net debt position of -16.13M. Total book value stands at 41.77M, with working capital of 27.96M providing operational flexibility.
| Cash & Cash Equivalents | 16.13M |
| Total Debt | 2.41M |
| Net Debt | -16.13M |
| Equity (Book Value) | 41.77M |
| Book Value Per Share | 2.28 |
| Working Capital | 27.96M |
Medistim ASA produced 19.52M in operating cash flow over the twelve months ended September 30, 2026.
| Operating Cash Flow | 19.52M |
| Free Cash Flow | 19.52M |
| FCF Per Share | 1.07 |
Over the twelve months ended September 30, 2026, Medistim ASA posted a gross margin of 81.68, reflecting its pricing power and cost economics. The operating margin of 28.62 and net profit margin of 22.41 provide insight into operational efficiency.
| Gross Margin | 81.68 |
| Operating Margin | 28.62 |
| Pretax Margin | 28.91 |
| Profit Margin | 22.41 |
| EBITDA Margin | 30.11 |
Over the twelve months ended September 30, 2026, Medistim ASA paid dividends of 0.73 per share. The dividend payout ratio of 82.04 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.64, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.27, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medistim ASA shareholders.
| Dividend Per Share | 0.73 |
| Payout Ratio | 82.04 |
| Shareholder Yield | 3.27 |
| FCF Yield | 4.64 |
Already premium?